IRRAS AB publishes Interim Report for the period January to March 2020
Rapid adaptation of the sales process due to covid-19 and preparations for commercial expansion ”The events that occurred during the first quarter of 2020 have challenged us to quickly adapt our global medical technology business to support our customers and the patients who need our life-saving technologies. Among other actions, we have strengthened our resources for support to physicians and patients, particularly through digital channels. After securing the CE Mark recertification of IRRAflow in late December, our EU launch of the product resumed. IRRAflow inventory is in stock in